Project Grant SB1HL174312
Award Date
9/17/24
Completion Date
8/31/26
Dollars Obligated
$251K
Federal Agency
National Heart Lung and Blood Institute
Awardee
City Labs, Inc. (LD55BB3D8EM7)
Federal Grant Program
93.837
Assistance Type
Project Grant
Place of Performance
Miami, FL 33186, USA
Similar Awards
The National Heart, Lung, and Blood Institute (NHLBI) awarded a $732,221 Project Grant under the Cardiovascular Diseases Research program (CFDA 93.837) to The Johns Hopkins University. The grant supports research to develop an mRNA-based "biological pacemaker" as an alternative to implantable cardiac pacemaker devices. The objective is to evaluate the clinical feasibility and safety of using mRNA-lipid nanoparticle complexes to reprogram ventricular myocytes into pacemaker cells,...
The National Heart, Lung, and Blood Institute (NHLBI) awarded a $323,230 Project Grant under the Cardiovascular Diseases Research program (CFDA 93.837) to Sirona Medical Technologies, Inc. The goal of this R61 phase project is to develop and validate hardware that will interface Sirona's proprietary catheter technologies with radiofrequency (RF) and pulsed field (PF) energy generator platforms. This will establish the signal parameters required for the safe and effective delivery of ablative...
The National Heart, Lung, and Blood Institute (NHLBI) awarded a $1,283,558 Project Grant under the Cardiovascular Diseases Research federal grant program (CFDA 93.837) to the Massachusetts Institute of Technology (MIT) for the development and demonstration of Multi-Electroplasmonic Nanoantenna Arrays (MENAS) to enable wireless, high-resolution transmembrane-level electrophysiological recording of cardiomyocyte action potentials. The four-year project, running from August 1, 2024 to July 31,...
The National Heart, Lung, and Blood Institute (NHLBI), a division of the National Institutes of Health (NIH), awarded a $298,368 Project Grant under the Cardiovascular Diseases Research (CFDA 93.837) federal grant program to Link Medical LLC, a for-profit limited liability company located in Chelsea, Michigan. The grant funding supports the development of a novel catheter-based technology to treat mitral valve regurgitation, a condition affecting millions of Americans. The project aims to...
The National Heart, Lung, and Blood Institute (NHLBI), part of the National Institutes of Health (NIH), awarded a $321,363 Project Grant under the Cardiovascular Diseases Research program (CFDA 93.837) to Nucleusrx, Inc., a small business located in Cranbury, NJ. The purpose of this 1-year SBIR Phase 1 project is to develop and test Nucleusrx's virtual care platform and remote intervention tool for post-acute care heart failure (HF) patients transitioning from the hospital to home. The goal is...
The National Heart, Lung, and Blood Institute (NHLBI), through its Cardiovascular Diseases Research Program (CFDA 93.837), awarded a $400,000 Project Grant to Electronic Biosciences, Inc., a small biotechnology company in San Diego, California. The grant supports the development of an advanced analytical testing device to quantitatively characterize lipoprotein particles in blood. Lipoproteins are key indicators of cardiovascular disease risk, as certain classes can contribute to the buildup...
The National Heart, Lung, and Blood Institute (NHLBI) of the National Institutes of Health (NIH) awarded Sigt LLC a $293,880 Project Grant under the Cardiovascular Diseases Research (CFDA 93.837) program. The purpose of this Phase 1 SBIR grant is to develop a novel "Intraoperative Cardiac Pulsed Field Ablation Lesion Assessment System" (PFA-LAS) that can monitor procedure parameters and confirm durable lesion formation during cardiac pulsed electric field ablation procedures for atrial...
This federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) provides $275,396 to Link Biosystems Inc., a self-certified small disadvantaged business, to develop bioreactor technologies for efficient differentiation, scale-up, and maturation of induced pluripotent stem cell (iPSC)-derived cardiomyocytes. The research aims to address challenges in producing clinically relevant quantities of...
This federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), provides $437,461 to 3DT Holdings, LLC to develop a novel stabilization catheter for His pacing lead implants. The goal is to improve the accuracy and ease of placing pacing leads in the His bundle to deliver cardiac resynchronization therapy for heart failure patients. The project aims to refine the design of a deployable suction-tipped...
The National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research (CFDA 93.837) program, awarded a $310,948 Project Grant to Minnesota Healthsolutions Corporation, a for-profit woman-owned small business, on September 15, 2023. The grant funds the development of an adaptable platform to support patients with behavior change interventions aimed at improving adherence to treatment and prevention for multiple chronic diseases. The platform will utilize remote...